



Certificate of Analysis

Human Interferon Alpha 4a (Alpha M1)

Catalog No: 11177-1

Lot No: 7395

Size: $\geq 1 \times 10^5$ units

Description: Recombinant Human Interferon Alpha 4a (Alpha M1) (Hu-IFN- α M1)

Volume: 0.100 ml

Activity: 1.26×10^6 units/ml (MDBK/VSV)

Specific Activity: 4.20×10^8 units/mg (MDBK/VSV)

Buffer: Phosphate buffered saline (PBS) containing 0.1% bovine serum albumin (BSA)

Endotoxin: < 1 EU/ μ g

Molecular Weight: 19.4 kDa

Purity: $\geq 95\%$

Purification Method: Purified from *E. coli* by a combination of Ion Exchange, Hydrophobic Interaction and Size Exclusion Chromatography

Source: cDNA obtained from human leukocyte mRNA expressed in *E. coli*

Human Gene: IFNA4

Synonyms: Hu-IFN- α M1

Accession Number: NM_021068

Assay Used to Measure Bioactivity: Interferon was titrated with the use of the cytopathic effect inhibition assay as listed

Bovine (MDBK/VSV) – Performed as described [Rubinstein, *et al.* (1981) *J. Virol.* 37 (2):755]. The EC₅₀ for interferon in this assay is ~ 5 U/ml. Lot Activity was derived from multiple determinations in the above assay.

Human (A549/EMCV) – Performed as described [Budd, *et al.* (1985) *Canc. Chem. Pharm.* 12:39]. The EC₅₀ for interferon in this assay is ~ 1 U/ml. **Activity:** 5.41×10^5 units/ml **Specific Activity:** 1.80×10^8 units/mg

The units are determined by use of a Human IFN Alpha A (Hu-IFN- α A [2a]) laboratory standard calibrated to the international reference standard for Human Interferon Alpha A (Hu-IFN- α A [2a]) provided by the National Institutes of Health [Meager, *et al.* (2001) *J. Immunol. Meth.* 257 (1-2):17-33]. Please note that IFN assays vary between labs and assay systems [Meager, *et al.* (2001) *J. Immunol. Meth.* 257:17. Meager and Das (2005) *J. Immunol. Meth.* 306:1].

Shipping Conditions: Dry Ice

Physical State of Product During Shipping: Frozen

Storage Conditions/Comments: After receipt, the product may be stored at -20°C for short-term use (≤ 6 months). For long-term storage, we recommend storing the product at -70°C or below for retention of full activity. When thawing, the contents of the tube should be apportioned in separate tubes so that freezing and thawing is kept to a minimum. Refreezing should be done on dry ice or in a dry ice/alcohol bath. Further dilution of the product should be in buffers containing protein such as 0.1% bovine serum albumin (BSA) or tissue culture media with serum. Dilution of material below 2×10^5 units/ml for freezing is not recommended. One freeze-thaw cycle is equivalent to thawing an aliquot prepared from the material received. [The activity measured after one freeze-thaw cycle is 1.34×10^6 units/ml (MDBK/VSV)]. For more information on protein handling, visit our Resource Library at www.pbl assaysci.com.



pbl assay science

131 Ethel Road West, Suite 6 | Piscataway, NJ 08854 USA | T:+1.732.777.9123 | F:+1.732.777.9141 | E: info@pbl assaysci.com | W: pbl assaysci.com


Authorization

Released by: _____ 

Date: June 21, 2021

Sold under license from Pestka Biomedical Laboratories, Inc. d/b/a PBL Assay Science. For research use only. Not for diagnostic or clinical use in, or administration to, humans. Not for resale in original or any modified form, including inclusion in a kit, for any purpose. Not for use in the preparation of any commercial product.

Rev. 03

A decorative graphic at the bottom of the page consisting of a wavy, multi-colored shape transitioning from light green on the left to bright blue on the right.